Earnings season is in full swing, but what holds the key for the market's next move? » Read More
Goldman Sachs just upgraded Deere to buy from neutral.
Shares of Ambarella rose about 9.3 percent Friday on the heels of better-than-expected quarterly results.
May's jobs report is likely an anomaly, but it wipes out any chance the Fed will raise interest rates this month, Jan Hatzius says.
Sterne Agee CRT initiated coverage of Tesla with a buy rating.
Broadcom's stock rose about 5 percent Friday after the firm posted quarterly profits that were well above expectations.
Shares of Talen Energy soared 17 percent Friday after announcing it was being acquired by Riverstone Holdings.
Shares of Gogo shed more than 16 percent Friday after rival company ViaSat won a major contract with American Airlines.
Todd Gordon of TradingAnalysis.com predicts that Visa will continue climbing and gives his trade.
In exclusive content for CNBC Pro subscribers, Bob Pisani explains his views on what could take the market to a new high.
Some of the names on the move ahead of the open.
In his June investment outlook, Bill Gross contended that bond and stock returns realized in the last 40 years can't be repeated.
The May jobs report shocked a market that was preparing for a possible Fed rate increase this summer. So how do you trade it?
Jim Cramer gets the appeal of Tesla, but could the auto stocks be a value trap? He revealed how to play the connected car revolution.
Jim Cramer goes off the charts to determine what old and new technology could add to a portfolio.
Concordia Healthcare traded nearly 10 percent lower.
Tesla's Elon Musk may think Apple could be a serious competitor when it introduces a car, but analyst Andrew Uerkwitz is skeptical.
Check out the companies making headlines after the bell Thursday: Broadcom, Ambarella, Gap and more.
The growth of connected devices take place much faster than people think over the next few years, Cisco CEO Chuck Robbins says.
Biotech startup NantHealth launched into the market Thursday after its initial public offering, with the stock surging nearly 33 percent.
Dermira's investors were feeling the heat Thursday as the biotechnology stock slid more than 4 percent.